SCCM Resource Library-Update on FDA CAR-T Products and Toxicity Management Guidelines

Update on FDA CAR-T Products and Toxicity Management Guidelines

Video Transcription

Video Summary

The speaker discusses the updates on FDA-approved CAR T-cell products and their toxicity profiles. CAR T-cell therapy is a type of genetically engineered immune cells that can overcome tumor's immune system and launch a powerful immune response. However, this therapy can also cause significant toxicities, including cytokine release syndrome (CRS) and neurotoxicity syndrome known as ICANS. The mainstay of treatment for CRS is targeting IL-6 with tocilizumab, while ICANS is managed with global immune suppression using corticosteroids. Anakinra, an IL-1 receptor antagonist, may also be considered in specific cases. Overall, CAR T-cell therapy shows promise, but careful management of toxicities is necessary.

Asset Subtitle

Pharmacology, 2023

Asset Caption

Type: one-hour concurrent | Evolving Landscape in Critical Care Medicine: Cellular Therapy-Related Toxicity (SessionID 1202444)

Meta Tag

Content Type Presentation

Knowledge Area Pharmacology

Membership Level Professional

Membership Level Select

Tag Toxicology

Year 2023

Keywords

FDA-approved CAR T-cell products

toxicity profiles

cytokine release syndrome

neurotoxicity syndrome

IL-6 targeting with tocilizumab

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.